The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

The reason why Daan Gene took the initiative to cut the prices of several test reagents is that the market demand for such test reagents has not yet reached a large scale, and it is doubtful whether it is feasible to exchange price for volume.

Agilent Technologies said after the close of the market on Monday that its fiscal fourth quarter revenues grew 11 percent year over year and beat the consensus Wall Street estimate.

Al Jalila Children's Specialty Hospital, based in Dubai, United Arab Emirates, said on Monday that it has signed a deal with Illumina to collaborate on rapid whole-genome sequencing for diagnosing critically ill children.

The overall overseas revenue of listed china companies has a three-year CAGR of more than 25%, and the export volume will rebound significantly in 2022.

ANP Technologies has received Emergency Use Authorization from the US Food and Drug Administration for its NIDS COVID-19 Antigen Home Test, according to the agency said on Thursday.

Innova Medical Group and iXensor said Thursday they have reached a distribution deal covering Europe for the Phronesia Smart Ovulation Test, an Innova-branded assay using iXensor's technology.

The MedTech 100 is a financial index calculated using the Medtech Big 100 companies covered in Medical Design and Outsourcing. The Big 100 is a collection of top medtech companies ranked by annual revenue, R&D spend and employee headcount.

Thermo Fisher Scientific said on Tuesday that it has priced an offering of $1.2 billion of senior notes and an offering of €1.25 billion of senior notes.

Biodesix said on Thursday that it has priced a public offering of 30.5 million shares of its stock at $1.15 apiece for expected gross proceeds of $35.1 million.

Burning Rock Biotech said late Tuesday that its Q3 revenues were up 22 percent year over year, driven by higher volumes of the companies test kits for use in hospitals.